A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure
Ramucirumab for advanced hepatocellular carcinoma in the current real world: A Japanese single-arm study post-REACH-2 (The R-evolution Study)
Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Endosomal Recycling Inhibitors Downregulate the Androgen Receptor and Synergise with Enzalutamide
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer
Development and characterization of fused human arginase I for cancer therapy
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper